ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1360

Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Abstract Number: 1361

The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis
Abstract Number: 1362

Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Abstract Number: 1363

Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years’ Follow-Up (ESPOIR Cohort)
Abstract Number: 1364

Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group
Abstract Number: 1365

Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings
Abstract Number: 1366

Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study
Abstract Number: 1367

Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
Abstract Number: 1368

Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
Abstract Number: 1369

Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
Abstract Number: 1370

Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
Abstract Number: 1371

DMARD Utilization Pattern in Older Adults with Rheumatoid Arthritis
Abstract Number: 1372

Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.
Abstract Number: 1373

The Effect of Methotrexate on Lipid and Apolipoprotein Levels in RA Goes Hand-in-hand with EULAR Response
Abstract Number: 1374

Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].